The term Cyp3a13 Activators refers to a class of chemical compounds that exhibit the unique capability to interact with and modulate the activity of the cytochrome P450 3A13 (CYP3A13) enzyme. CYP3A13 is a member of the cytochrome P450 superfamily of enzymes, which are predominantly found in the liver and play a significant role in metabolizing a wide range of endogenous and exogenous compounds. CYP3A13, in particular, is predominantly expressed in the murine (mouse) liver and is involved in the metabolism of various substrates, including drugs, xenobiotics, and endogenous compounds. Cyp3a13 activators are compounds that can influence the enzymatic activity or expression of CYP3A13, affecting the metabolism of its substrates.
The mechanism of action of Cyp3a13 activators typically involves their ability to modulate the activity or expression of the CYP3A13 enzyme. These activators may interact with CYP3A13 directly, altering its enzymatic activity, substrate specificity, or expression levels. Alternatively, they may influence the cellular signaling pathways and transcriptional regulators that govern CYP3A13 expression, indirectly impacting its function. Understanding the properties and effects of Cyp3a13 activators is important in the field of drug metabolism and toxicology, as it can provide insights into the factors that influence the metabolism and clearance of various drugs and xenobiotics in murine models. Additionally, it can contribute to a broader understanding of the role of cytochrome P450 enzymes in drug metabolism and the regulation of endogenous compound levels in rodents.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Induces CYP3A13 expression by activating pregnane X receptor (PXR). | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Glucocorticoid that can induce CYP3A13 expression via glucocorticoid receptor-mediated mechanisms. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Indirectly increases CYP3A13 expression through PXR activation. | ||||||
Carbamazepine | 298-46-4 | sc-202518 sc-202518A | 1 g 5 g | $33.00 $71.00 | 5 | |
Induces CYP3A13 expression, potentially through PXR activation. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
May increase CYP3A13 expression through peroxisome proliferator-activated receptor gamma (PPARγ) activation. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Activates PPARα, potentially influencing CYP3A13 expression. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
Could enhance CYP3A13 expression through PPARγ activation. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Indirectly influences CYP3A13 by modulating transcription factors involved in its expression. | ||||||